Caffeine, creatine, GRIN2A and Parkinson's disease progression

David K. Simon(Beth Israel Deaconess Medical Center), Tianzhong Yang(University of Minnesota), Richard B. Dewey(Southwestern Medical Center), Peng Wei(Creighton University), Pei Shieen Wong(Singapore General Hospital), Christine Klein(University of Lübeck), Cai Wu(The University of Texas Health Science Center at Houston), Barbara C. Tilley(The University of Texas Health Science Center at Houston), Susen Schaake(University of Lübeck), Saloni Sharma(University of Nebraska–Lincoln), Haydeh Payami(University of Alabama at Birmingham), Anne‐Marie Wills(Harvard University Press), Daniel Truong(University of California, Los Angeles), Jacquelyn Bainbridge(University of Colorado Anschutz Medical Campus), Robert A. Hauser(University of South Florida), Caroline M. Tanner(University of California, San Francisco), Jay S. Schneider, Michael J. Aminoff, Carlos Singer(University of Miami Health System), Katja Lohmann(University of Lübeck)
Journal of the Neurological Sciences
February 17, 2017
10.1016/j.jns.2017.02.032
Cited by 33

Related Papers

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
|The Lancet|2014|2.7k
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
|JAMA|2015|2.5k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Genetics of Parkinson's Disease
|Cold Spring Harbor Perspectives in Medicine|2012|1.4k